Novel ligands of steroid hormone receptors

Bibliography

• EVANS RM: The steroid and thyroid hormone receptor superfamily. Science (1988) 240:889–895.
   PubMed Web of Science ®Google Scholar
• CARSON-JURICA MA, SCHRADER WT, O'MALLEY BW: Steroid receptor family: structure and functions. Endocr. Rev. (1990) 11:201–220.
   PubMed Web of Science ®Google Scholar
• O'MALLEY BW, TSAI M-J: Overview of the steroid receptor superfamily of gene regulatory proteins. In: Steroid and Hormonal Action. Parker MG (Ed.), IRL, Oxford, UK (1993):45–63.
   Google Scholar
• •An introduction to the transcriptional aspects of intracellular receptors.
   Google Scholar
• KUMAR MV, TINDALL DJ: Transcriptional regulation of the steroid receptor genes. Prog. Nucleic Add Res. Mol. Biol. (1998) 59:289–304.
   Google Scholar
• •An update of recent developments in the superfamily of steroid/thyroid hormone receptors.
   Google Scholar
• MISRAHI M, LOOSFELT H, ATGER M et al.: Cloning and immunolocalization of human and rabbit proges-terone receptors. Prog. CancerRes. Ther. (1988) 35:27–33.
   Google Scholar
• ARRIZA JL, WEINBERGER C, CERELLI G et al: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science (1987) 237:268–275.
   PubMed Web of Science ®Google Scholar
• WEINBERGER C, HOLLENBERG SM, ONG ES et al.: Identi-fication of human glucocorticoid receptor comple-mentary DNA clones by epitope selection. Science (1985) 228:740–742.
   PubMedGoogle Scholar
• CHANG C, KOKONTIS J, LIAO S: Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (1988) 240:324–326.
   PubMed Web of Science ®Google Scholar
• MULATERO P, VEGLIO F, PILON C et al.: Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexametha-sone and long polymerase chain reaction for chimeric gene. J. Clin. Endocrinol Metab. (1998) 83:2573–2575.
   PubMed Web of Science ®Google Scholar
• NEEF G, BEIER S, ELGER W, HENDERSON D, WIECHERT R: New steroids with antiprogestational and antigluco-corticoid activities. Steroids (1984) 44:349–372.
   PubMed Web of Science ®Google Scholar
• KUMAR R, THOMPSON EB: The structure of the nuclear hormone receptors. Steroids (1999) 64:310–319
   PubMed Web of Science ®Google Scholar
• •An introduction to the overall protein structures of intracel-lular receptors.
   Google Scholar
• TANENBAUM DM, WANG Y, WILLIAMS SP, SIGLER PB: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. ScL USA (1998) 95:5998–6003.
   PubMed Web of Science ®Google Scholar
• •A very interesting comparison of the LBDs of ER and PR with generalised predictions.
   Google Scholar
• MAALOUF GJ, XU W, SMITH TF, MOHR SC: Homology model for the ligand-binding domain of the human estrogen receptor. J. Biomof Struct. Dyn. (1998) 15:841–851.
   PubMed Web of Science ®Google Scholar
• EVANS RM: Molecular characterization of the glucocor-ticoid receptor. Recent Prog. Horm. Res. (1989) 45:1–27.
   PubMedGoogle Scholar
• YANG-YEN HF, CHAMBARD JC, SUN YL et al.: Transcrip-tional interference between c-Jun and the glucocorti-coid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell (1990) 62:1205–1215.
   PubMed Web of Science ®Google Scholar
• VAN DER BURG B, LIDEN J, OKRET S et al.: Nuclear factor kappa B repression in anti-inflammation and immunosuppression by glucocorticoids. Trends Endocrinol. Metab. (1997) 8:152–157.
   Google Scholar
• BRATTSAND R, LINDEN M: Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment. Pharmacol Ther. (1996) 10:81–92.
   PubMed Web of Science ®Google Scholar
• HECK S, KULLMANN M, GAST A et al.: A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBOJ (1994) 13:4087–4095.
   PubMed Web of Science ®Google Scholar
• HECK S: Transcriptional repression as molecular basis of the anti-inflammatory action of glucocorticoids [PhD thesis]. Wiss. Ber. Forschungszent., Univ. Karlsruhe (1998):1–110. ISSN FZKA 6087.
   Google Scholar
• ••An exceptional summary of transcriptional repression as thepredominant mode of action for the anti-inflammatory effects of glucocorticoids.
   Google Scholar
• FURR BJ, PATTERSON JS, RICHARDSON DN, SLATER SR, WAKELING AE: Tamoxifen. Pharmacol. Biochem. Prop. Drug Subst. (1979) 2:355–399.
   Google Scholar
• HEEL RC, BROGDEN RN, SPEIGHT TM, AVERY GS: Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs (1978) 16:1–24.
   PubMed Web of Science ®Google Scholar
• MOONEY AG: Development of tamoxifen (IC146, 474), a nonsteroidal estrogen antagonist with antitumor activity. Prog. Chem other. (Antibacterial, Antiviral, Antineoplast.), 8th Proc. Int. Congr. Chemother. (1974) 3:359–633.
   Google Scholar
• GRESE TA, DODGE JA: Selective estrogen receptor modulators (SERMs). Curr. Pharm. Des. (1998) 4:71–92.
   PubMed Web of Science ®Google Scholar
• ••An outstanding review of the SAR of SERMs.
   Google Scholar
• BRZOZOWSKI AM, PIKE ACW, DAUTER Z et al.: Molecular basis of agonism and antagonism in the estrogen receptor. Nature (1997) 389:753–758.
   PubMed Web of Science ®Google Scholar
• ROY S, DATTA JK, KUMARI GL: Clinical and biological studies with centchroman. Recent Adv. Reprod. Regul Fend., Proc. Symp. (1979) 359–66.
   Google Scholar
• SAEED A, SHARMA AP, DURANI N et al.: Structure-activity relationship of antiestrogens. Studies on 2,3-diary1-1-benzopyrans. J. Med. Chem. (1990) 33:3210–3216.
   Google Scholar
• SHARMA AP, SAEED A, DURANI S, KAPIL RS: Structure-activity relationship of antiestrogens. Effect of the side chain and its position on activity of 2,3-diary1-2H-1-benzopyrans. J. Med. Chem. (1990) 33:3216–3222.
   Google Scholar
• SHARMA AP, SAEED A, DURANI S, KAPIL RS: Structure-activity relationship of antiestrogens. Phenolic analogs of 2,3-diary1-2H-1-benzopyrans. J. Med. Chem. (1990) 33:3222–3229.
   Google Scholar
• BINDAL RD, KATZENELLENBOGEN JA: Bis-(4-hydroxyphenyl) [2-(phenoxysulfonyl) phenyl]-methane: isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfonphthalein). J. Med. Chem. (1988) 31:1978–1983.
   PubMed Web of Science ®Google Scholar
• BITMAN J, CECIL HC: Estrogenic activity of DDT analogsand polychlorinated biphenyls. J. Agr. Food Chem. (1970) 18:1108–1112.
   PubMed Web of Science ®Google Scholar
• DANSE IR, JAEGER RJ, KAVA R et al: Public healthconcerns about environmental polychlorinated biphenyls (PCBs). Ecotoxicol Environ. Sal (1997) 38:71–84.
   PubMed Web of Science ®Google Scholar
• ARNOLD SF, KLOTZ DM, COLLINS BM et al: Synergisticactivation of estrogen receptor with combinations of environmental chemicals. Science (1996) 272:1489–1492.
   PubMed Web of Science ®Google Scholar
• GAO H, KATZENELLENBOGEN JA, GARG R, HANSCH C: Comparative QSAR analysis of estrogen receptor ligands. Chem. Rev. (1999) 99:723–744.
   PubMed Web of Science ®Google Scholar
• MCDONNELL DP, NORRIS JD, PAIGE LA et al: Peptide antagonists of the estrogen receptor. Nature (1999) 285:744–746.
   Google Scholar
• ZHI L, MARSCHKE KB: Novel class of non-steroidal progesterone receptor antagonists. Exp. Opin. Ther. Patents (1999) 9(6):695–700.
   Web of Science ®Google Scholar
• ALLAN G, MACIELAG M: Progesterone receptor agonists and antagonists. Exp. Opin. Ther. Patents (1999) 9(7)955–962.
   Google Scholar
• ZHI L, TEGLEY CM, MARSCHKE KB et al.:5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification. J. Med. Chem. (1999) 42:1466–1472.
   PubMed Web of Science ®Google Scholar
• TEGLEY CM, ZHI L, MARSCHKE KB et al.:5-Benzylidene-1,2-dihydrochromeno[3,4-f] quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J. Med. Chem. (1998) 41:4354–4359.
   Google Scholar
• •The first non-steroidal functional PR ligands.
   Google Scholar
• ZEELEN FJ: Medicinal chemistry of steroids. Princ. Med.Biol. (1997) 88:427–463.
   Google Scholar
• NEWLING DW: Anti-androgens in the treatment of prostate cancer. Br. J. Urol. (1996) 77:776–784.
   PubMedGoogle Scholar
• DALTON JT, MUKHERJEE A, ZHU Z, KIRKOVSKY L, MILLER DD: Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun. (1998) 244:1–4.
   PubMed Web of Science ®Google Scholar
• •Discussion of the first non-steroidal AR agonists.
   Google Scholar
• BATTMANN T, BRANCHE C, BOUCHOUX F et al: Pharma-cological profile of RU 58642, a potent systemic antian-drogen for the treatment of androgen-dependent disorders. J. Steroid Biochem. Mol. Biol. (1998) 64:103–111.
   PubMed Web of Science ®Google Scholar
• COUSTY-BERLIN D, BERGAUD B, BRUYANT MC et al:Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite. J. Steroid Biochem. Mol. Biol. (1994) 51:47–56.
   Google Scholar
• TEUTSCH G, GOUBET F, BATTMANN T et al.: Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J. Steroid Biochem. Mol Biol. (1994) 48:111–119.
   PubMed Web of Science ®Google Scholar
• HAMANN LG, HIGUCHI RI, ZHI L et al.: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J. Med. Chem. (1998) 41:623–629.
   PubMed Web of Science ®Google Scholar
• EDWARDS JP, WEST SJ, POOLEY CLF et al.: New nonster-oidal androgen receptor modulators based on 4-(trifluoromethyl)-2 (11-1)-pyrrolidino [3,2-g]quinoli-none. Bioorg. Med. Chem. Lett. (1998) 8:745–750.
   PubMed Web of Science ®Google Scholar
• HAMANN LG, MANI NS, DAVIS RL et al: Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4 -ethyl-1,2,3, 4-tetrahydro- 6- (trifluoro-methyl)-8-pyridono[5,6-g]-quinoline (LG121071). J. Med. Chem. (1999) 42:210–212.
   PubMed Web of Science ®Google Scholar
• ZHI L, TEGLEY CM, MARSCHKE KB, JONES TK: Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino-[3,2-g]quinolinone. Bioorg. Med. Chem. Lett. (1999) 9:1009–1012.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of antagonist/agonist interchange withsubtle structural variations.
   Google Scholar
• HIGUCHI RI, EDWARDS JP, CAFERRO TR et al.: 4-Alkyl- and 3,4-dialky1-1,2,3,4-tetrahydro-8-pyridono-[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists. Bioorg. Med. Chem. Lett. (1999) 9:1335–1340.
   PubMed Web of Science ®Google Scholar
• HORI Y, ABE Y, NAKAJIMA H et al.: WB 2838 [3-chloro-4-(2-amino-3-chloropheny1)-pyrrole]: non-steroidal androgen-receptor antagonist produced by a Pseudomonas. J. Antibiot. (1993) 46:1327–1333.
   Google Scholar
• HORI Y, ABE Y, NAKAJIMA H et al: W59761 A and B: new non-steroidal androgen-receptor antagonists produced by a Streptomyces. J. Antibiot. (1993) 46:1901–1903.
   Google Scholar
• SUTANTO W, DE KLOET ER: Mineralocorticoid receptorligands: biochemical, pharmacological, and clinical aspects. Med. Res. Rev. (1991) 11:617–639.
   PubMed Web of Science ®Google Scholar
• ESPINER EA: Mineralocorticoids. Basic Clin. Endocrinol (1984) 4:371–401.
   Google Scholar
• CALLEJA C, PASCUSSI JM, MANI JC et al.: The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nature Med. (1998) 4:92–96.
   PubMed Web of Science ®Google Scholar